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that can be used to counsel male patients with OAB symptoms in pre-
dicting the presence of BOO.
IPD14:
DIABETES MELLITUS PATIENTS REQUIRE HIGHER RATES OF
CONTINUING MEDICATION AFTER TRANSURETHRAL RESECTION OF
PROSTATE: IMPLICATIONS FROM TAIWAN NATIONWIDE POPULATION-
BASED COHORT STUDY
Chen-Pang Hou, Phei-Lang Chang, Chien-Lun Chen, Yu-Hsiang Lin, Pei-
Shan Yang, Ke-Hung Tsui. Department of Urology, Chang Gung Memorial
Hospital, Taoyuan, Taiwan
Purpose: The aim of this study was to compare the clinical outcomes
between diabetic patients and non-diabetic patients receiving transure-
thral resection of prostate (TUR-P).
Materials and Methods: This analysis was a retrospective cohort study
using 13 years (2000e2012) of claims data from Taiwan’s National Health
Insurance Research Database (NHIRD). A total of 4887 patients who had
persistent lower urinary tract symptoms (LUTS) and underwent TUR-P for
benign prostate hyperplasia (BPH) were enrolled and divided into two
groups: Diabetes mellitus (DM) group and Non-DM group. The patients’
characteristics, post-operative clinical outcomes, and the medication re-
cords after TUR-P were compared.
Results: Therewas no difference between the two groups in regards to age,
ratio of urinary tract infection (UTI) and urinary retention before surgery.
The pre-operative medication statuses were also similar between the two
groups. However, DM group patients had a higher prevalence of comor-
bidities. Post-operatively, the DM group had lower rates of UTI (OR, 0.78;
p¼0.009) and higher rates of urinary retention requiring catheterization
(OR, 1.35; p¼0.01) within 1 month after TUR-P. Both of the proportions
became insigniﬁcantly different during the 1 month to 1 year post-oper-
ative period. A higher proportion of patients with DM took anti-musca-
rinics (OR, 1.23; P ¼ 0.032) within the ﬁrst 3 months and a-blockers (OR,
1.18; P¼ 0.049) during 3e12months after receiving TUR-P. Overall, the DM
group patients had a worse post-operative medication-free survival
compared to that of non-DM group patients (95% CI¼1.14; p¼0.005).
Conclusion: Diabetes Mellitus patients require higher rates of continuing
medication after TUR-P, especially anti-muscarinics in three months post-
op and alpha-blocker after three months post-op. Diabetes Mellitus pa-
tients also had higher incidence of urine retention after surgery.
IPD15:
ONE-YEAR ANATOMIC OUTCOMES OF LAPAROSCOPIC SACROCOL-
POPEXY IN KAMEDA MEDICAL CENTER
Ting-Wen Huang, Jimmy Masayoshi Nomura, Shingo Moriyama, Shino
Tokiwa. Urogynecology Center, Kameda Medical Center, Japan
Purpose: For pelvic organ prolapse (POP) patients, voiding dysfunction is
associated with the increasing severity of cystocele. After surgical
correction of the prolapse, 89% patients had normalization of voiding
dysfunction (Fitzgerald MP, 2000). Prolapse repair surgery plays an
important role to resolve female lower urinary symptoms. Particularly,
laparoscopic sacrocolpopexy (LSC) provides the outcomes of the gold
standard abdominal approach while offering the beneﬁts of minimally
invasive surgery (Gabriel B, 2011). Since 2014, LSC became a new option for
POP patients covered by public health insurance in Japan. The aim of this
study is to clarify the postoperative anatomical change after LSC in Kameda
Medical Center.
Materials and Methods: We did a retrospective medical chart review
between April and December 2014 for patients who underwent LSC and
being followed up for one year in our center. The anatomical change was
assessed by using POP-Q. Recurrence rate and speciﬁc site were also
investigated.
Results: A total of 146 patients, aged 65.1±7.8, with average BMI 23.4±2.8,
were retrospectively enrolled. Average blood loss was 22.8±25.7ml with
238.5±45.3 minutes in operation time. For anatomical change assessed by
POP-Q, Aa changed from 1.1±1.4 to 2.9±0.3; Ba changed from 2.5±2. to
2.9±0.4; C changed from 1.4±3 to 7.4±1.4;gh changed from 4.4±1.1 to3.7±0.8; pb changed from 3.5±0.7 to 3.7±0.5; tvl changed from 8.1±1.1 to
8.6±1.2; Ap changed from 0±1.6 to 2.8±0.6; Bp changed from 0.6±2.4 to
2.7±0.7; D changed from 3.2±2.5 to 8.3±1.4. Aa, Ba, C, gh, tvl, Ap, Bp,
and D of POP-Q showed signiﬁcant differences between pre- and post-
operation. 8 patients (5.5%) showed recurrence during ﬁrst year after LSC.
2 patents were found to have recurrent anterior vaginal wall prolapse
while 7 patients had recurrent posterior wall prolapse. However, using
PFDI-20 to assess the feeling of a bulge for recurrent patients, no one felt a
bulge in the vaginal area.
Conclusion: POP patients receiving LSC showed signiﬁcant improvement
in anatomical outcome. Rate of recurrence in ﬁrst year after LSC was
about 5%.
IPD16:
EFFECTIVENESS OF NO-CGMP AXIS FOR LOWER URINARY TRACT
SYNDROME
Yukihide Matsui, Yurika Ito, Tomo Shimizu, Yota Nakajima, Toshihiro
Shimizu, Mizuki Kasahara, Koji Tamura, Toshihiro Tai, Masato
Nagata, Humito Yamabe, Kuri Aoki, Hideyuki Kobayashi, Koichi
Nagao, Koichi Nakajima. Department of Urology, Faculty of Medicine, Toho
University, Japan
Purpose: It is well known NO-cGMP axis plays a critical role in treatment
for erectile dysfunction. NO-cGMP axis is expected to not only ED but also
LUTS treatment due to regulate the smooth muscle relaxation. ZalutiaⓇ is
one of the PDE5 inhibitor launched in Japan on 2013 for LUTS treatment.
We evaluated the effectiveness of ZalutiaⓇ for LUTS and ED treatment.
Material and Methods: Between October 2014 and December 2015, 108
patients were prescribed ZalutiaⓇ 5mg per day in Toho University Medical
center Omori Hospital. Of 36patients were clinically evaluable such as PSA
level, prostate volume, IPSS (International prostate symptom score),
ﬂowmetry, EHS (erectile hardness score) and the diary of voiding.
Results: Effective rate for urinary symptoms, especially storage symptoms
including nocturia, daytime frequency and urgency, was 53% and for ED
was 76%. Medication discontinuance was noted 13 cases. 5 cases were due
to no effective, 2 were due to appearance of a new symptom and 6 were
due to side effect including hated erecting. Though there was no
improvement of the urinary symptom, 5 patients wanted to continue the
medication.
Conclusion: PDE5 inhibitor is safe and effective for LUTS treatment. PDE5
inhibitor gives an effect to erectile function supplementary and seems to
help not only the urinary symptoms but also the men's health.
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IPD17:
OPERATING TIMES AND CLINICAL OUTCOMES IN PERCUTANEOUS
NEPHROLITHOTOMY: A COMPARISON OF TRACT DILATION METHODS
Kuo-Kang Feng, Yuan-Ju Lee, I-Ni Chiang, Sho-Mon Wang, Kuo-How
Huang, Hong-Chiang Chang. Department of Urology, National Taiwan
University Hospital, College of Medicine, National Taiwan University, Taipei,
Taiwan
Purpose: The study investigated that two different tract dilatation method
affect operating times and bleeding complications associated with
percutaneous nephrolithotomy (PCNL) in the single-center study.
Materials and Methods: All patients who underwent PCNL for primary or
secondary treatment of kidney stone indications during the study period
(January, 2013 to August, 2015) were eligible for inclusion. PCNL pro-
cedures were performed according to local clinical guidelines and prac-
tices. Nephrostomy tract dilation was performed using balloon dilation or
Amplatz serial dilation. Hematologic complications assessed included
bleeding rates, transfusion rates, and preoperative and postoperative he-
moglobin values. Hospital stay (days) and the stone free rate are also
included into outcome parameters.
Results: The median operating time with balloon dilation (n ¼ 142) was
signiﬁcantly shorter than Amplatz serial dilation (n ¼54) at 88.0 vs 135.9
minutes, respectively (P < 0.0001). In the balloon dilation group, there was
